Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C27H21N3O5 |
Molecular Weight | 467.4727 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@]12C[C@](O)(C(=O)OC)[C@](C)(O1)N3C4=CC=CC=C4C5=C6CNC(=O)C6=C7C8=CC=CC=C8N2C7=C35
InChI
InChIKey=KOZFSFOOLUUIGY-SOLYNIJKSA-N
InChI=1S/C27H21N3O5/c1-26-27(33,25(32)34-2)11-18(35-26)29-16-9-5-3-7-13(16)20-21-15(12-28-24(21)31)19-14-8-4-6-10-17(14)30(26)23(19)22(20)29/h3-10,18,33H,11-12H2,1-2H3,(H,28,31)/t18-,26+,27+/m1/s1
Molecular Formula | C27H21N3O5 |
Molecular Weight | 467.4727 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
K-252a, a metabolite isolated from the culture broth of Nocardiopsis sp. K-252a, was found to exhibit an extremely potent inhibitory activity on protein kinase C. The IC50 value was 32.9 nM. K252a is a potent inhibitor of various protein kinases including Protein kinase A, Protein kinase C and
Protein kinase G. It acts by competition with the ATP binding site with Ki values of 18-25 nM. K252a also acts as a specific and potent inhibitor (IC50 = 3 nM) of
Trk receptors and thus selectively blocks the effects of nerve growth factor (NGF) on PC12 cells. At lower concentrations, K252a can act as a neuroprotective compound, promoting survival of primary neuronal
cultures. This alkaloid induces apoptosis and cell cycle arrest by inhibiting Cdc2 and Cdc25.4 Recently, K252a was found to improve psoriasis in a
SCID mouse-human skin model and to suppress referred mechanical hypersensitivity and neuropeptide up-regulation associated with acute pancreatitis.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/25710032
Curator's Comment: K252a does not cross the blood-brain barrier
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2093867 |
0.58 µM [IC50] | ||
Target ID: CHEMBL2815 |
2.4 nM [IC50] | ||
Target ID: CHEMBL2708 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12388555 |
5.0 nM [IC50] | ||
Target ID: CHEMBL2111324 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2393389 |
1.7 nM [IC50] | ||
Target ID: CHEMBL5585 Sources: https://www.ncbi.nlm.nih.gov/pubmed/?term=12118367 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT00995969
1.0 g K-252a (CT 327) cream will be applied to one target lesion twice daily
Route of Administration:
Topical
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2837190
K-252a inhibited PMN PKC (IC50 = 0.58 uM), and caused a concentration-dependent (0.1-10 uM) inhibition of degranulation elicited with the chemotactic peptide, N-formyl-methionyl-leucyl-phenylalanine (FMLP), the lipid agonists, 5(S), 12(R)-dihydroxy-5,14-cis-8,10-trans eicosatetraenoic acid (LTB4) and acetyl-sn-glyceryl-3-phosphorylcholine (AGEPC), and phorbol 12-myristate 13-acetate.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 19:17:44 GMT 2023
by
admin
on
Fri Dec 15 19:17:44 GMT 2023
|
Record UNII |
IV7H45AM5B
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C2089
Created by
admin on Fri Dec 15 19:17:45 GMT 2023 , Edited by admin on Fri Dec 15 19:17:45 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
K252A
Created by
admin on Fri Dec 15 19:17:45 GMT 2023 , Edited by admin on Fri Dec 15 19:17:45 GMT 2023
|
PRIMARY | |||
|
C1382
Created by
admin on Fri Dec 15 19:17:45 GMT 2023 , Edited by admin on Fri Dec 15 19:17:45 GMT 2023
|
PRIMARY | |||
|
3035817
Created by
admin on Fri Dec 15 19:17:45 GMT 2023 , Edited by admin on Fri Dec 15 19:17:45 GMT 2023
|
PRIMARY | |||
|
DB02152
Created by
admin on Fri Dec 15 19:17:45 GMT 2023 , Edited by admin on Fri Dec 15 19:17:45 GMT 2023
|
PRIMARY | |||
|
IV7H45AM5B
Created by
admin on Fri Dec 15 19:17:45 GMT 2023 , Edited by admin on Fri Dec 15 19:17:45 GMT 2023
|
PRIMARY | |||
|
DTXSID40880065
Created by
admin on Fri Dec 15 19:17:45 GMT 2023 , Edited by admin on Fri Dec 15 19:17:45 GMT 2023
|
PRIMARY | |||
|
99533-80-9
Created by
admin on Fri Dec 15 19:17:45 GMT 2023 , Edited by admin on Fri Dec 15 19:17:45 GMT 2023
|
PRIMARY | |||
|
43616
Created by
admin on Fri Dec 15 19:17:45 GMT 2023 , Edited by admin on Fri Dec 15 19:17:45 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> INHIBITOR | |||
|
TARGET -> INHIBITOR | |||
|
TARGET -> INHIBITOR | |||
|
TARGET -> INHIBITOR | |||
|
TARGET -> INHIBITOR | |||
|
TARGET -> INHIBITOR | |||
|
TARGET -> INHIBITOR | |||
|
TARGET -> INHIBITOR | |||
|
TARGET -> INHIBITOR | |||
|
TARGET -> INHIBITOR | |||
|
TARGET -> INHIBITOR | |||
|
TARGET -> INHIBITOR | |||
|
TARGET -> INHIBITOR | |||
|
TARGET -> INHIBITOR | |||
|
TARGET -> INHIBITOR | |||
|
TARGET -> INHIBITOR | |||
|
TARGET -> INHIBITOR | |||
|
TARGET -> INHIBITOR | |||
|
TARGET -> INHIBITOR |